<DOC>
	<DOCNO>NCT01707264</DOCNO>
	<brief_summary>Dose escalation study determine maximum tolerate dose NEOD001 approximately 30 subject AL amyloidosis . Expansion phase evaluate safety , efficacy pharmacokinetics NEOD001 25 additional subject maximum tolerate dose .</brief_summary>
	<brief_title>Phase 1/2 , Open Label , Dose Escalation Study NEOD001 Subjects With Light Chain ( AL ) Amyloidosis</brief_title>
	<detailed_description>The purpose dose escalation phase study determine maximum tolerated dose/Phase 2 recommend dose NEOD001 give single agent intravenously approximately 30 subject AL amyloidosis . The purpose expansion phase study evaluate safety , preliminary efficacy pharmacokinetics single agent NEOD001 maximum tolerate dose/Phase 2 recommend dose approximately 25 additional evaluable subject .</detailed_description>
	<mesh_term>Amyloidosis</mesh_term>
	<criteria>1 . Males female age â‰¥18 year ; 2 . ECOG performance status ( PS ) 02 ; 3 . Diagnosis systemic AL amyloidosis ( subject nonAL amyloidosis eligible ) ; 4 . Received least one prior systemic therapy , may include stem cell transplant , AL amyloidosis ; 5 . Have adequate organ function ; 6 . Ability understand willingness sign inform consent prior initiation study procedure . 1 . Secondary familial amyloidosis ; 2 . Life expectancy &lt; 3 month ; 3 . Symptomatic multiple myeloma ; 4 . Hypersensitivities monoclonal antibody ; 5 . Known HIV infection ; 6 . Women lactate ; 7 . Any condition prior therapy , opinion PI , would make subject unsuitable study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>AL amyloidosis</keyword>
	<keyword>Primary amyloidosis</keyword>
</DOC>